A detailed history of Fairman Group, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Fairman Group, LLC holds 13 shares of CSTL stock, worth $362. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Previous 13 -0.0%
Holding current value
$362
Previous $283,000 31.1%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Mar 26, 2024

BUY
$12.19 - $22.43 $158 - $291
13 New
13 $281,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $734M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Fairman Group, LLC Portfolio

Follow Fairman Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairman Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairman Group, LLC with notifications on news.